C-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas

Journal of Pathology

Volumn 234, Issue 2, 2014, Pages 190-202

  Sioletic, Stefano ^a   Czaplinski, Jeffrey ^a   Hu, Lan ^a   Fletcher, Jonathan A ^b   Fletcher, Christopher D M ^b   Wagner, Andrew J ^a   Loda, Massimo ^a,b   Demetri, George D ^a   Sicinska, Ewa T ^a   Snyder, Eric L ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autotaxin; C Jun; ENPP2; Liposarcoma; Soft tissue sarcoma

Indexed keywords

AUTOTAXIN; PROTEIN C JUN; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; PHOSPHODIESTERASE;

ARTICLE; CARCINOGENESIS; CELL MIGRATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; IN VITRO STUDY; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; ANIMAL; C-JUN; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL MOTION; ENPP2; GENETICS; HUMAN; LIPOSARCOMA; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SARCOMA; SOFT TISSUE TUMOR;

AUTOTAXIN; C-JUN; ENPP2; LIPOSARCOMA; SOFT TISSUE SARCOMA;

ANIMALS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL MOVEMENT; HUMANS; LIPOSARCOMA; MICE; PHOSPHORIC DIESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-JUN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84907961419     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4379     Document Type: Article

References (53)

1. Shaulian E. AP-1 - the Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 2010; 22: 894-899.
2. Angel P, Hattori K, Smeal T, et al. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988; 55: 875-885.
3. Maki Y, Bos TJ, Davis C, et al. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci USA 1987; 84: 2848-2852.
4. Bohmann D, Bos TJ, Admon A, et al. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1987; 238: 1386-1392.
5. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-136.
6. Langer S, Singer CF, Hudelist G, et al. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol 2006; 27: 345-352.
7. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J 2002; 21: 4104-4113.
8. Podar K, Raab MS, Tonon G, et al. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res 2007; 67: 1680-1688.
9. Rangatia J, Vangala RK, Singh SM, et al. Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPa DNA binding via leucine zipper domain interaction. Oncogene 2003; 22: 4760-4764.
10. Vleugel MM, Greijer AE, Bos R, et al. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 2006; 37: 668-674.
11. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868.
12. Young MR, Li JJ, Rincón M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 1999; 96: 9827-9832.
13. Jin SP, Kim JH, Kim MA, et al. Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol Oncol Res 2007; 13: 284-289.
14. Yamamoto K, Miyatsuka T, Tanaka A, et al. Tissue-specific deletion of c-Jun in the pancreas has limited effects on pancreas formation. Biochem Biophys Res Commun 2007; 363: 908-914.
15. Eferl R, Sibilia M, Hilberg F, et al. Functions of c-Jun in liver and heart development. J Cell Biol 1999; 145: 1049-1061.
16. Chibon F, Mariani O, Derré J, et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer 2004; 40: 32-37.
17. HenricksWH, Chu YC, Goldblum JR, et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21: 271-281.
18. Rosai J, Akerman M, Dal Cin P, et al. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol 1996; 20: 1182-1189.
19. Pedeutour F, ForusA, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999; 24: 30-41.
20. Snyder EL, Sandstrom DJ, LawK, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009; 218: 292-300.
21. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-721.
22. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007; 11: 361-374.
23. Horvai AE, DeVries S, Roy R, et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol 2009; 22: 1477-1488.
24. Kamijyo A SK. Establishment of human alveolar soft sarcoma cell line ASPS-KY. J Jpn Orthop Assoc 2005;79.
25. Snyder EL, Sandstrom DJ, LawK, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009; 218: 292-300.
26. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999; 13: 607-619.
27. Gatza CE, Oh SY, Blobe GC. Roles for the type III TGFβ receptor in human cancer. Cell Signal 2010; 22: 1163-1174.
28. Singh S, Barrett J, Sakata K, et al. ETS proteins and MMPs: partners in invasion and metastasis. Curr Drug Targets 2002; 3: 359-367.
29. Shaikhibrahim Z, Wernert N. ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 [review]. Int J Oncol 2012; 40: 1748-1754.
30. Steller MD, Shaw TJ, Vanderhyden BC, et al. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 2005; 3: 50-61.
31. Houben AJ MW. Autotaxin and LPA receptor signaling in cancer. Cancer Metast Rev 30: 557-565.
32. Kawagoe H, Stracke ML, Nakamura H, et al. Expression and transcriptional regulation of the PD-Ia/autotaxin gene in neuroblastoma. Cancer Res 1997; 57: 2516-2521.
33. Zhang G, Zhao Z, Xu S, et al. Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J (Engl) 1999; 112: 330-332.
34. Yang SY, Lee J, Park CG, et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metast 2002; 19: 603-608.
35. Stassar MJ, Devitt G, Brosius M, et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 2001; 85: 1372-1382.
36. Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005; 7: 7-16.
37. Yang Y, Mou Lj, Liu N, et al. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 1999; 21: 216-222.
38. Baumforth KR, Flavell JR, Reynolds GM, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 2005; 106: 2138-2146.
39. Masuda A, Nakamura K, Izutsu K, et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 2008; 143: 60-70.
40. Saunders LP, Ouellette A, Bandle R, et al. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Therap 2008; 7: 3352-3362.
41. Jankowski M. Autotaxin: its role in biology of melanoma cells and as a pharmacological target. Enzyme Res 2011; 2011: 194857.
42. Nam SW, Clair T, Campo CK, et al. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000; 19: 241-247.
43. Nam SW, Clair T, Kim YS, et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001; 61: 6938-6944.
44. Black EJ, Clair T, DelrowJ, et al. Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 2004; 23: 2357-2366.
45. Farina AR, Cappabianca L, Ruggeri P, et al. Constitutive autotaxin transcription by Nmyc-amplified and non-amplified neuroblastoma cells is regulated by a novel AP-1- and SP-mediated mechanism and abrogated by curcumin. FEBS Lett 2012; 586: 3681-3691.
46. Gotoh M, Fujiwara Y, Yue J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 2012; 40: 31-36.
47. Boucharaba A, Serre CM, Guglielmi J, et al. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103: 9643-9648.
48. Park SY, Jeong KJ, Panupinthu N, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 2011; 30: 1351-1359.
49. So J, Wang FQ, Navari J, et al. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 2005; 97: 870-878.
50. Albers HM, Dong A, van Meeteren LA, et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci USA 2010; 107: 7257-7262.
51. Gupte R, Patil R, Liu J, et al. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. Chem Med Chem 2011; 6: 922-935.
52. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006; 26: 5015-5022.
53. ZhangH,XuX,Gajewiak J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009; 69: 5441-5449.